Radezolid is under clinical development by Melinta Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Radezolid’s likelihood of approval (LoA) and phase transition for Acne Vulgaris took place on 20 Dec 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Radezolid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RX-1741 (radezolid) is under development for the treatment of acne vulgaris and bacterial vaginosis. The therapeutic candidate is administered topically, orally and intravenously. The drug candidate is a second generation oxazolidinone that acts on 23S rRNA. It is developed using ribosome crystallography platform. It was also under development for osteomyelitis, community-acquired bacterial pneumonia, methicillin-resistant Staphylococcus Aureus (MRSA) infections, mycobacterium tuberculosis Infections, uncomplicated skin and skin structure infections (uSSSI).
Melinta Therapeutics overview
Melinta Therapeutics (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta’s products and pipeline candidates are built on a ribosome platform licensed from Yale University. Melinta is headquartered in New Haven, Connecticut, the US.
Quick View Radezolid LOA Data
|Highest Development Stage|